in caveolin-1-deficient mice. 13 Moreover, we have recently reported that pharmacological inhibition of EGFR prevents AAA development induced by AngII plus BAPN, which was associated with suppression of endoplasmic reticulum (ER) stress, oxidative stress, and interleukin-6 and matrix metalloproteinases-2 expression. 10 However, whether VSMC-specific ADAM17 expression is essential for signal transduction leading to AAA development or any pharmacological ADAM17 intervention prevents AAA development remains unclear. In the present study, we tested the hypothesis that genetic silencing of VSMC ADAM17 or systemic ADAM17 inhibitory antibody treatment prevents AAA formation induced by AngII plus BAPN.
Materials and Methods

Animal Protocol
All animal procedures were performed with prior approval from Temple University Institutional Animal Care and Use Committee and in accordance with National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice deficient in VSMC ADAM17 (ADAM17 flox/flox Sm22α-Cre +/− ) were generated as reported.
14 At 8 to 10 weeks of age, male ADAM17 flox/flox Sm22α-Cre +/− mice and littermate male control, ADAM17
flox/flox Sm22α-Cre −/− , mice were infused with AngII (Bachem; 1 μg/kg·per minute) for 4 weeks and BAPN (Tokyo Chemical Industry, 150 mg/kg·per day) for the first 2 weeks or control saline for 4 weeks (Alzet, Durect Corp). 13 In addition, 8-to 10-week-old male C57Bl6 mice (Jackson) were infused with AngII (1 μg/kg per min) for 4 weeks and received BAPN in drinking water (1 mg/mL) for the first 2 weeks together with human/mouse crossreactive ADAM17 inhibitory antibody A9B8 15 or control human IgG2 (Athens Research & Technology), which was solubilized in PBS and administered at 10 mg/kg·per day via intraperitoneal injection, at days 1, 7, 14, and 21. Control C57Bl6 mice were sham-operated.
The AngII plus BAPN-induced mouse model of aortic aneurysm reproducibly induces AAA with morphological and histological characteristics similar to human AAA, but without enhancing atherosclerosis, as seen in other AngII-dependent AAA models. 12 Aortic luminal diameter at maximal dilation was measured using high-resolution 2-dimensional imaging (B mode) with high-frequency ultrasound (VisualSonics Vevo2100) on day 0, 14, 21, and 28 of the study. The treatment protocols were blinded to the evaluator. Despite the original article reporting incidence of thoracic aortic aneurysm in this model (38%), 12 we consistently observed much less thoracic aortic aneurysm(0%-10%). 10, 13 Therefore, quantitative evaluation was not performed in thoracic aortas. Blood pressure and heart rate were evaluated in the conscious state at day 28 by telemetry (DSI equipped with ADInstrument 6 software) via carotid catheter (PA-C10 transmitter). For animals that died before the completion of the study, necropsy was performed when possible to define the causes of death. The thoracic aorta or abdominal aorta rupture as a cause of death was defined with the presence of hematoma in thoracic or abdominal cavity, respectively. After 28 days, mice were euthanized, perfused with formalin, and dissected for tissue samples. Abdominal aortas were extracted and subjected to paraffin embedding. Sections were stained with a standard Masson's trichrome protocol 8 to distinguish medial area from adventitia. Images were visualized on an Olympus IX81 inverted microscope using an Olympus SC30 high-resolution camera and acquired with Olympus cellSens Entry 1.11 software.
Immunohistochemistry
Sections from abdominal aortas were deparaffinized and blocked in 5% goat serum and 1% BSA for 1 hour at room temperature, incubated with primary antibody in PBS containing 1% BSA and 0.1% Tween 20 overnight at 4°C followed by biotinylated secondary antibody for 90 minutes at room temperature. The sources and dilutions of the primary antibodies used in this study are provided in Table  S1 in the online-only Data Supplement. Slides were incubated with avidin-biotin peroxidase complex for 30 minutes at room temperature, and staining was visualized with the substrate diaminobenzidine (Vector), which produced a brown color, and counterstained with hematoxylin. An equal concentration of control IgG was used side-byside with each antibody to ensure staining specificity. Quantification of the antibody staining was performed as reported previously with subtraction of IgG background staining. 13 All images were visualized on Olympus SC30 high-resolution camera and acquired with Olympus cellSens Entry 1.11 software using the same exposure time. Images were loaded into the ImageJ program (http://rsb.info.nih. gov/ij) for analysis. A region of interest was drawn around the entire aorta with the freehand selection tool. Adventitia was excluded from the quantification because the adventitia areas were limited in aortas except those with AAA. All images were set to the same hue, saturation, and brightness. The area and intensity (integrated density) in the region of interest were then measured and analyzed. Data were obtained from 3 to 4 nonoverlapping fields per aortic cross-section for each antibody (n=4 aortas per treatment or genotype). Results are presented as fold increase over control, which was set at 1.
Statistical Analysis
Data from the groups were analyzed by 1-way analysis of variance with Tukey's multiple comparison test (C57Bl6 mice with basal, AAA treatment, or AAA treatment plus ADAM17 antibody), 2-way analysis of variance with Bonferroni post-tests (ADAM17 wild-type or deficient mice with or without AAA treatment), or log-rank (Mantel-Cox) test (Kaplan-Meier survival curves) using GraphPad Prism version 5.0C for Macintosh. Data were presented as mean±SEM. Statistical significance was taken at P<0.05.
Results
There was a significant difference in survival rates between mice deficient with VSMC ADAM17 (100%) and littermate control mice (47.6%) when treated with AngII plus BAPN over the 28-day observational period ( Figure 1A ). Based on necropsy, all confirmed deaths were caused by aortic rupture. Surviving control mice, as well as mice deficient in VSMC ADAM17, treated with AngII plus BAPN developed comparable degree of hypertension ( Figure 1B ; Table S2 ). All surviving AngII plus BAPN-treated control mice developed AAA, with significant enlargements of the maximum diameter of abdominal aortas. In contrast, VSMC ADAM17-deficient mice with AngII plus BAPN treatment had significantly less aortic diameter enhancement compared with control mice (Figure 2 ; Figures S1 and S2) .
Histological analysis demonstrated that AAAs induced by AngII plus BAPN in control mice were associated with vascular fibrosis/matrix deposition and disruption of medial layer structures. In addition, enhanced EGFR activation, increased expression of ADAM17, matrix metalloproteinases-2, and interleukin-6, and enhanced ER stress (Lys-Asp-Glu-Leu), oxidative stress (nitro-tyrosine), and leukocyte infiltration (CD45) were observed with semiquantitative immunohistochemical staining. These AAA-associated responses were attenuated in VSMC ADAM17-deficient mice. However, tumor necrosis factor-α (TNFα) expression did not show any statistical differences among the groups (Figures S3 through S6) .
To ascertain that ADAM17 represents a novel therapeutic target to prevent AAA development, C57Bl6 mice treated with AngII plus BAPN were injected with a human/mouse cross-reactive ADAM17 inhibitory antibody. Distinct from VSMC ADAM17 silencing, there was no statistical difference in the survival rate with the ADAM17 antibody treatment ( Figure 3A) . The ADAM17 antibody treatment did not alter hypertension induced by AngII plus BAPN ( Figure 3B ; Table  S3 ). However, AAA development was significantly reduced in mice treated with the ADAM17 antibody compared with the control IgG treatment (Figure 4 ; Figures S7 through S9).
Discussion
Enhanced ADAM17 expression 9 and downstream EGFR activation 10 have been reported in human AAA samples. Requirement of ADAM17 in CaCl 2 -induced AAA has also been reported with inducible systemic ADAM17 deletion. 9 However, our study provides new information that AngIIdependent AAA development and rupture are markedly prevented in mice lacking VSMC ADAM17 and that pharmacological intervention of ADAM17 can attenuate AAA in a mouse model. Limited VSMC-specific mechanisms are known to contribute to AAA in animal models, which includes decreased catalase 16 and activation of Notch1, 17 whereas induction of hypoxia-inducible factor-1α in VSMCs seems protective. 18 In VSMCs stimulated with AngII, ADAM17-dependent shedding produces EGFR ligands, such as heparin-binding epidermal growth factor-like growth factor leading to EGFR transactivation. 19 Because EGFR inhibition also prevents AngII plus BAPN-mediated AAA development and rupture, 10 VSMC EGFR most likely mediates the ADAM17-dependent function in this mouse model of AAA. On activation, EGFR mediates several downstream responses in VSMCs, including oxidative stress, 20 ER stress, 8 and intereukin-6 induction. 21 These downstream effects were also evident in the present study, thus, likely contributing to AAA development ( Figure  S10 ). 16, 22, 23 In addition, enhanced vascular ER and oxidative stress further promote immune cell infiltration, which is also critical for AAA development. 4 Therefore, the findings demonstrated in this article suggest that all of these mechanisms are potentially mediated by a single but multifunctional metalloprotease ADAM17 specifically expressed in VSMCs. However, additional experiments are desired to track these mechanisms before the establishment of AAA. It is also ideal to use a distinct model of AAA to generalize our findings, which are limitations in this study.
While we confirmed a previously suggested EGFRdependent mechanism as a downstream signal of VSMC ADAM17, our findings cannot exclude other and potentially new mechanism(s) through which ADAM17 contributes to AAA development. Other ADAM17 substrates, including TNFα, Notch1, and angiotensin-converting enzyme 2, may also participate in AAA pathology according to literature. 17, 24, 25 Note that while the protein expression analysis of TNFα did not show any enhancement in AAA, the experiment did not measure the potential conversion of pro-TNFα to mature and active TNFα by ADAM17. Moreover, ADAM17 has additional diverse substrates and many regulatory mechanisms. 26 Therefore, further research is required to identify potentially new pathways through which ADAM17 regulates AAA.
The AngII plus BAPN model consistently produces AAA associated with hypertension, but without enhancing atherosclerosis, as observed in other AngII-dependent AAA models, including hyperlipidemic mice. 12 Incidence of AAAs in normolipidemic mice with AngII infusion alone is low, 27 even though AngII infusion is sufficient for ADAM17 induction and EGFR activation in the vasculature, including the aorta. 8 Therefore, we surmise that ADAM17/EGFR activation is required to advance AAA but insufficient to initiate AAA, which requires an additional signal or condition such as those primed by BAPN or hyperlipidemia.
In the present study, a discrepancy was observed in survival rates between VSMC ADAM17 deletion with mixed background mice and systemic ADAM17 inhibition with C57BL6 mice. This may be because of significantly higher blood pressure in C57BL6 mice, regardless of the ADAM17 antibody or control IgG treatment. The discrepancy could also be because of distinct genetic background of the mice and distinct cell type-specific roles (promoting versus preventing rupture in AAA) of ADAM17. In addition to the medial layer, enhanced ADAM17 expression was also observed in endothelium and adventitia of AAA, a finding that is in agreement with prior published work. 13 Because the promoter used to target ADAM17 is relatively specific to smooth muscle, 14 we assume that attenuation of AAA by silencing VSMC ADAM17 results in prevention of endothelial and adventitial ADAM17 induction by AngII plus BAPN. In addition to VSMC ADAM17, the ADAM17 antibody likely inhibited endothelial and adventitial ADAM17 in the present study. Therefore, the roles of endothelial and adventitial ADAM17 in AAA require further study.
Perspectives
Our findings highlight the critical role of ADAM17 in mediating AAA development and rupture. We propose that VSMC ADAM17 is a needed component for EGFR transactivation contributing to ER stress and oxidative stress in AAA. Our results also indicate that ADAM17 inhibition can be a valuable treatment option for AAA. However, it remains to be explored how the VSMC ADAM17 signal communicates with other cell type-specific mechanisms presented before. 
Sources of Funding
Disclosures
None. 
